Delivery Order SPE2DB22D2206-SPE2DB25FKC23
- Not listed
- The Defense Logistics Agency awarded a $23,543.70 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is scheduled for completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $35,816.58 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. Performance will be executed from the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $23,495.73 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with a completion date of September 11, 2025, and performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,822.71 to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to a qualified vendor. The work is to be completed by September 25, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of RINVOQ ER 30 mg tablets (30-unit packages) valued at $34,458.64. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement with an ultimate completion date of July 15, 2025. The award supports the agency's pharmaceutical supply chain requirements, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,605.35 on August 20, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,847.74 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement requirements. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $12,446.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-set-aside contract represents a small-value pharmaceutical procurement fulfilling federal medical supply requirements. The award was made to AmerisourceBergen's Corporate Office division, located in Conshohocken, Pennsylvania, which serves as the company's primary...
- The Defense Logistics Agency awarded a $39,787.21 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a completion date of June 2, 2025. This competitively awarded, firm fixed-price contract was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical supply delivery under AmerisourceBergen's broader relationship with the...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKC23Delivery Order
The Defense Logistics Agency (DLA) awarded a $27,586.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 30 mg tablets (30-unit bottles), with a completion date of September 25, 2025. The award was made on September 24, 2025, with no set-aside designation, indicating it was competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies a comprehensive range of medications and medical products to support military healthcare systems and other federal medical procurement needs. The company's extensive federal contract portfolio demonstrates its critical role in supplying brand-name and generic pharmaceuticals, vaccines, and specialized medical commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.6k | 9/24/25 |